Milrinone

Milrinone is a phosphodiesterase inhibitor, a cardiotonic drug with positive inotropic and vasodilating effects, which can be used to treat acute or chronic refractory congestive heart failure.

Millinone is a cardiotropic drug, belonging to phosphodiesterase inhibitors. By inhibiting phosphodiesterase, the drug can increase the concentration of cyclic adenosine phosphate and calcium in cardiomyocytes, thereby effectively strengthening myocardial contractility and increasing cardiac output, so as to exert positive muscle strength. In addition, Milrinone can also play a vasodilator role by directly acting on the small arteries.

milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

יש לנו הרבה מפעלים איכותיים עם שיתוף פעולה עמוק, שיכולים לספק לכם מוצרים באיכות גבוהה ומחירים תחרותיים. ואנחנו יכולים גם לתת הנחות עבור רכישות בכמויות גדולות. ואנו משתפים פעולה עם חברות שילוח מקצועיות רבות, יכולים לספק מוצרים בבטחה וחלקה לידיים שלך. זמן אספקה ​​הוא כ 3-20 ימים לאחר אישור התשלום.

Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.

1. האם אתה מפעל או חברת סחר?
אנחנו חברה המשלבת תעשייה ומסחר, מספקת שירות חד פעמי. OEM יכול להתקבל.

2. האם אתה מספק דוגמאות? האם זה בחינם או נוסף?
דגימות חינם. יש לשלם את דמי ההובלה של המדגם לצדך.

3. האם יש לך תעודות הקשורות לבקרת איכות?
אישור ISO 9001:2008 להבטחת איכות.

4. מה עלי לספק כדי לקבל הצעת מחיר?
אנא הודע לנו על סוג המוצר שאתה צריך, כמות הזמנה, כתובת ודרישות ספציפיות. הצעת המחיר תבוצע לעיונך בזמן.

5. איזה סוג של שיטת תשלום אתה מעדיף? איזה סוג של תנאים מקובלים?
תנאי משלוח מקובלים: FOB,CFR,CIF,EXW;
מטבע תשלום מקובל: דולר;
סוג תשלום מקובל: T/T, ווסטרן יוניון; Paypal, אבטחת סחר.
שפה מדוברת: אנגלית.